



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Amivantamab

| | |
|-----------|---|
| Cat. No.: | HY-P9977 |
| CAS No.: | 2171511-58-1 |
| Target: | EGFR |
| Pathway: | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|--------------------|---|
| Description | Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells ^[1] . |
| In Vitro | Amivantamab (JNJ-61186372)(0.05-1 mg/mL) results in a significant and dose-dependent decrease in the viability of Ba/F3 cells, as well as a significant decrease in phosphorylated EGFR (pEGFR), phosphorylated AKT (pAKT), phosphorylated ERK (pERK) and phosphorylated S6 (pS6) of the EGFR downstream signaling pathway ^[2] . Amivantamab (JNJ-61186372) has potent antitumor activity in NSCLC patient-derived cancer cells with EGFR Exon20ins mutations through downregulation of EGFR and MET signaling pathways ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Amivantamab (JNJ-61186372)(i.p, 30 mg/kg, twice a week, 15 days)effectively reduces tumour volume in female thymus-free BALB-c/nu mouse xenograft model of NSCLC with EGFR Exon20ins mutation and has in vivo anti-tumour effects ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol.* 2021 Oct 20;39(30):3391-3402.

[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. *Cancer Discov.* 2020 Aug;10(8):1194-1209.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA